Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06548048 · ClinicalTrials.gov registry record · NA
Dietary Supplementation on Fat Oxidation
A NA study of Obesity and Overweight, sponsored by Brightseed.
- Recruiting
- Registry status
- NA
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT06548048: Recruiting NA study of Obesity and Overweight, sponsored by Brightseed.
NCT06548048 is a NA study of Obesity and Overweight that is actively recruiting participants, run by Brightseed. The registered enrollment target is 16 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06548048, a NA study of Obesity and Overweight, is actively recruiting participants, sponsored by Brightseed.
- RECRUITING
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this pilot study is to evaluate the effects of 4 weeks of daily consumption of encapsulated N-trans-caffeoyl tyramine (NCT) and N-trans-feruloyl tyramine (NFT) at a dose of 120 mg/d on measures of fat oxidation in women with overweight or obesity. The hypothesis is that fat oxidation at rest (measured via indirect calorimetry) and over a 24 h period (measured via d31-palmitic acid stable isotope tracer) will be higher in the group receiving the active study product compared to the control product at the end of the 4-week consumption period.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Dietary supplement containing plant derived phenolics
- DIETARY_SUPPLEMENT Microcrystaline cellulose
Study Locations (1)
Illinois
- Biofortis - Addison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2024-07-31 |
| Est. Completion | 2024-12-31 |
| Phase | NA |
What NCT06548048 shows while recruiting
NCT06548048 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Dietary supplement containing plant derived phenolics is the first listed.
NCT06548048 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06548048 about?
NCT06548048 is a clinical study titled "Dietary Supplementation on Fat Oxidation". The purpose of this pilot study is to evaluate the effects of 4 weeks of daily consumption of encapsulated N-trans-caffeoyl tyramine (NCT) and N-trans-feruloyl tyramine (NFT) at a dose of 120 mg/d on measures of fat oxidation in women with overweight or obesity. The hypothesis is that fat oxidation ...
What is the current status of trial NCT06548048?
This trial is currently recruiting. It is a NA study. The enrollment target is 16 participants. The study started on 2024-07-31. Estimated completion is 2024-12-31.
What conditions does trial NCT06548048 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT06548048?
The interventions under investigation include: Dietary supplement containing plant derived phenolics (DIETARY_SUPPLEMENT), Microcrystaline cellulose (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06548048?
This trial is sponsored by Brightseed, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06548048 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06548048's enrollment target sits among peer trials
16 993rd of 1053 higher than 56 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
RECRUITING · NA
-
Tai Chi as a Novel Strategy to Increase Physical Activity Among Adults Pursuing Metabolic and Bariatric Surgery
RECRUITING · NA
-
Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG)
RECRUITING · NA
-
SMARTer Weight Loss Management
RECRUITING · NA
-
HealthyTogether: RCT of a Dyadic Weight Management Intervention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI